Pfizer (PFE) Q3 2026 Earnings Call: Guidance and Outlook
Pfizer raised its full-year 2026 revenue and adjusted diluted EPS guidance, reflecting strong performance through the third quarter and confidence in its strategic execution.
About Pfizer. Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide.
The company expects continued growth in non-COVID products driven by market performance and new indications.
Cost savings
The company is implementing a second phase of cost savings to deliver $2.5 billion from 2027 to 2029.
Obesity portfolio
Pfizer plans to advance 10 active and planned Phase III trials in 2026 for its obesity portfolio.
Capital allocation
Priorities remain unchanged, focusing on investing in the business, maintaining the dividend, and preserving flexibility for future value-enhancing actions.
LOE transition
Management expects leverage to remain around current levels or modestly higher during the LOE transition period.
Growth target
Pfizer maintains a line of sight to a risk-adjusted high single-digit revenue CAGR from year-end 2028 through year-end 2033.
Dombey's summary of the Pfizer Q3 2026 earnings call held Nov 3, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
